TY - JOUR
TI - Therapeutic effect of glibenclamide in a fixed combination with
metformin or phenformin in NIDDM patients
AU - Raptis, AE
AU - Tountas, NB
AU - Yalouris, AG
AU - Halvatsiotis, PG and
AU - Raptis, SA
JO - Hormone and Metabolic Research
PY - 1996
VL - 28
TODO - 2
SP - 89-94
PB - Georg Thieme Verlag
SN - 0018-5043, 1439-4286
TODO - 10.1055/s-2007-979135
TODO - antidiabetic tablets; glibenclamide; phenformin; metformin; NIDDM
TODO - The combination of a sulfonylurea with a biguanide improves the
pancreatic p-cell insulin secretion and the insulin utilization in
peripheral tissues in NIDDM. This open, crossover, randomised and
prospective study was designed to compare the effects of the fixed
combination glibenclamide-metformin (GL-METF) - 2.5 and 400 mg
respectively, with the fixed combination glibenclamide-phenformin
(GL-PHEN) - 2.5 and 25 mg respectively, on NIDDM diabetes control.
Thirty NIDDM patients, in ideal metabolic control, who were being
treated with GL-PHEN were divided in two groups. One group received
GL-PHEN for 12 weeks followed by 12 weeks treatment with GL-METF and the
reverse treatment was given to the second group. A statistically
significant decrease of post-prandial blood glucose (p = 0.034) and
glycosylated haemo-globin (p < 0.02) values was observed under GL-METF
treatment compared to those with GL-PHEN. The values of lactic acid were
within normal limits during both treatments. The insulin secretion after
breakfast was similar with both drug compounds. The BMI of the patients
remained the same during a follow-up study of 24 weeks. Lipid metabolism
did not change significantly during the trial and the safety parameters
(renal and liver function, full blood count) remained unchanged. In
conclusion, the administration of GL-METF leads to better diabetes
control in NIDDM patients compared to that of GL-PHEN.
ER -